Results 31 to 40 of about 1,082,218 (306)

Gut microbiota diversity is prognostic in metastatic hormone receptor‐positive breast cancer patients receiving chemotherapy and immunotherapy

open access: yesMolecular Oncology, EarlyView.
In this exploratory study, we investigated the relationship between the gut microbiota and outcome in patients with metastatic hormone receptor‐positive breast cancer, treated in a randomized clinical trial with chemotherapy alone or chemotherapy in combination with immune checkpoint blockade.
Andreas Ullern   +7 more
wiley   +1 more source

Eden Fisheries Advisory Committee 29th April, 1975 [PDF]

open access: yes, 1975
This is the report from the Eden Fisheries Advisory Committee meeting, which was held on the 29th April, 1975. It covers information on fishery byelaws, and a report by unit fisheries officer on fisheries activities.

core  

PYCR1 inhibition in bone marrow stromal cells enhances bortezomib sensitivity in multiple myeloma cells by altering their metabolism

open access: yesMolecular Oncology, EarlyView.
This study investigated how PYCR1 inhibition in bone marrow stromal cells (BMSCs) indirectly affects multiple myeloma (MM) cell metabolism and viability. Culturing MM cells in conditioned medium from PYCR1‐silenced BMSCs impaired oxidative phosphorylation and increased sensitivity to bortezomib.
Inge Oudaert   +13 more
wiley   +1 more source

Spring Semester 2009 [PDF]

open access: yes, 2009
A short-run newsletter published by the Student Athlete Advisory Committee of Providence College. (Spring Semester 2009 - 4 pages in total.

core   +1 more source

In vitro properties of patient serum predict clinical outcome after high dose rate brachytherapy of hepatocellular carcinoma

open access: yesMolecular Oncology, EarlyView.
Following high dose rate brachytherapy (HDR‐BT) for hepatocellular carcinoma (HCC), patients were classified as responders and nonresponders. Post‐therapy serum induced increased BrdU incorporation and Cyclin E expression of Huh7 and HepG2 cells in nonresponders, but decreased levels in responders.
Lukas Salvermoser   +14 more
wiley   +1 more source

Consensus Statement by the Expert Advisory Committee

open access: yesКардиоваскулярная терапия и профилактика, 2012
Тема: Место комбинированной гиполипидемической терапии (статин + эзетимиб) в лечении дислипидемий Дата: 09.10.2011 Место проведения: г. Москва Председатели: Президент ВНОК, акад. РАМН Р.Г.
article Editorial
doaj   +1 more source

Home Depot Foundation - 2009 Annual Report [PDF]

open access: yes, 2010
Contains videos of president's message, 2008 highlights, and national impact; program information; grantee profiles; grant information by state; awards; and lists of corporate donors, board members, staff, and supplier advisory committee ...

core  

Patient‐specific pharmacogenomics demonstrates xCT as predictive therapeutic target in colon cancer with possible implications in tumor connectivity

open access: yesMolecular Oncology, EarlyView.
This study integrates transcriptomic profiling of matched tumor and healthy tissues from 32 colorectal cancer patients with functional validation in patient‐derived organoids, revealing dysregulated metabolic programs driven by overexpressed xCT (SLC7A11) and SLC3A2, identifying an oncogenic cystine/glutamate transporter signature linked to ...
Marco Strecker   +16 more
wiley   +1 more source

Expanding conceptualizations of harm reduction: results from a qualitative community-based participatory research study with people who inject drugs

open access: yesHarm Reduction Journal, 2017
Background The perspectives of people who use drugs are critical in understanding why people choose to reduce harm in relation to drug use, what practices are considered or preferred in conceptualizations of harm reduction, and which environmental ...
L. M. Boucher   +12 more
doaj   +1 more source

Home - About - Disclaimer - Privacy